Relmada Therapeutics

Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment Long-term dosing with REL-1017 was well-tolerated, with…

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder See more here

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results See more here

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results See more here

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results See more here

Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors See more here

Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer See more here

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder See more here

Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results See more here

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder See more here